- Home
- LCTX vs GGR Comparison
LCTX vs GGR Comparison
Compare LCTX & GGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LCTX
- GGR
- Stock Information
- Founded
- LCTX 1990
- GGR 2011
- Country
- LCTX United States
- GGR Taiwan
- Employees
- LCTX N/A
- GGR N/A
- Industry
- LCTX Biotechnology: Biological Products (No Diagnostic Substances)
- GGR Auto Manufacturing
- Sector
- LCTX Health Care
- GGR Consumer Discretionary
- Exchange
- LCTX Nasdaq
- GGR Nasdaq
- Market Cap
- LCTX 118.8M
- GGR 114.3M
- IPO Year
- LCTX N/A
- GGR N/A
- Fundamental
- Price
- LCTX $0.41
- GGR $0.26
- Analyst Decision
- LCTX Strong Buy
- GGR Hold
- Analyst Count
- LCTX 5
- GGR 2
- Target Price
- LCTX $4.20
- GGR $0.50
- AVG Volume (30 Days)
- LCTX 1.8M
- GGR 615.5K
- Earning Date
- LCTX 03-10-2025
- GGR 05-08-2025
- Dividend Yield
- LCTX N/A
- GGR N/A
- EPS Growth
- LCTX N/A
- GGR N/A
- EPS
- LCTX N/A
- GGR N/A
- Revenue
- LCTX $9,499,000.00
- GGR $310,518,000.00
- Revenue This Year
- LCTX $25.10
- GGR N/A
- Revenue Next Year
- LCTX $35.67
- GGR $5.00
- P/E Ratio
- LCTX N/A
- GGR N/A
- Revenue Growth
- LCTX 6.19
- GGR N/A
- 52 Week Low
- LCTX $0.40
- GGR $0.26
- 52 Week High
- LCTX $1.56
- GGR $2.02
- Technical
- Relative Strength Index (RSI)
- LCTX 30.50
- GGR 20.61
- Support Level
- LCTX $0.47
- GGR $0.32
- Resistance Level
- LCTX $0.55
- GGR $0.36
- Average True Range (ATR)
- LCTX 0.04
- GGR 0.02
- MACD
- LCTX -0.00
- GGR -0.01
- Stochastic Oscillator
- LCTX 4.04
- GGR 0.08
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
About GGR Gogoro Inc.
Gogoro Inc is focused on eliminating the barriers to electric fuel adoption to bring swappable electric power within reach of every urban rider. Its battery swapping technology compromises an interoperable platform that seamlessly integrates a comprehensive ecosystem of hardware, software, and services, which consists of Gogoro Smart Batteries, GoStations, Gogoro Network Software & Battery Management Systems, Smartscooter, and related components and kits. Geographical presence in Taiwan and Other countries, majority of its revenue comes from Tiwan.